Pre-made Lumiliximab benchmark antibody ( Whole mAb, anti-FCER2/CD23 therapeutic antibody, Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lumiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-327-1mg	1mg	3090
GMP-Bios-ab-327-10mg	10mg	Inquiry
GMP-Bios-ab-327-100mg	100mg	Inquiry
GMP-Bios-ab-327-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lumiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody
INN Name	Lumiliximab
Target	CD23
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	3fzu:HL:CD
95-98% SI Structure	None
Year Proposed	2004
Year Recommended	2004
Companies	Biogen Idec
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia
Development Tech	na